| Metric | Value (₹ Cr) |
|---|---|
| Revenue | 657.16 |
| Total Income | 684.15 |
| Expenditure | 524.00 |
| PBT | 160.16 |
| Net Profit | 129.68 |
| OPM | 12.91% |
| NPM | 18.95% |
| EPS | 7.80 |
Inventurus Knowledge Solutions Ltd Reports 16% YoY Revenue Growth and 28% YoY PAT Growth for Q3 FY25
06 Feb 2025 · 6 Feb 2025, 03:26 am
Summary
Inventurus Knowledge Solutions Limited, a technology-enabled healthcare solutions provider, announced its financial results for the quarter ended December 31, 2024. The company reported a 16% YoY revenue growth and a 28% YoY PAT growth. EBITDA margins have crossed 30% this quarter, a significant improvement from the 24% proforma margin of FY2024.
Key Highlights
- 1
Revenue at ₹6,572 million (15.9% YoY / + 2.2% QoQ growth)
- 2
EBITDA at ₹2,006 million at 30.5% of revenue (24.3% YoY / +5.7% QoQ growth)
- 3
PAT at ₹1,297 million at 19.7% of revenue (27.7% YoY / 14.8% QoQ growth)
- 4
Adjusted PAT at ₹1,455 million at 22.1% of revenue (30.6% YoY / 12.8% QoQ growth)
- 5
Client Wins: Palomar Health & Palomar Health Medical Group, Radiology Partners, Western Washington Medical Group
- 6
New Launches: Fully AI-driven version of Scribble product
- 7
Industry Recognition & Awards: Best in KLAS for Medical Transcription Services for the 7th consecutive year, Top-ranked for Clinical Documentation & Medical Coding Services by Black Book Market Surveys, AQuity Solutions acquisition recognized as the Healthcare/Life Sciences Deal of the Year (>100MM) by M&A Advisor International Awards
Management Comments
Sachin K. Gupta
Founder and Chief Executive Officer at IKS Health
We continue our journey of improving profitability by transforming legacy AQuity’s operating model through technology and global human capital. EBITDA margins have crossed 30% this quarter, a significant improvement from the 24% proforma margin of FY2024. With revenue from our top five customers growing 19% and new client acquisitions ramping up, we are optimistic about sustained growth heading into the final quarter and the next financial year
Nithya Balasubramanian
Chief Financial Officer at IKS Health
We are steadily regaining our legacy IKS EBITDA margins. PAT growth has outpaced EBITDA growth due to lower finance costs as we continue to repay our debt. Adjusted PAT, excluding non-cash amortization of acquired intangibles, has improved by 31%. We will maintain our investments in technology and Al to drive superior outcomes and enhance customer satisfaction
Informational and educational content only. Not investment advice.